- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00524563
Clinical Outcomes and Global Epidemiology -Data Coordinating Center
June 11, 2018 updated by: University of Pittsburgh
The primary objective is to assess for independent predictors of in-hospital mortality (up to 28 days) in patients with Acinetobacter bloodstream infection.
Secondary Objectives include the following: To determine the impact of inactive empiric antimicrobial therapy, defined as receipt of empiric antimicrobial therapy with no in vitro activity against the offending isolate for at least 24hrs, on the outcome (end points defined below) of patients with Acinetobacter bloodstream infection.
To determine the impact of carbapenem resistance and pan-drug resistance (defined as resistance to all antimicrobials except colistin and/or tigecycline if these agents were tested) on the outcome of patients with Acinetobacter bloodstream infection.
To assess the efficacy of varying definitive therapies on the outcome of patients with Acinetobacter bloodstream infection.
To characterize the molecular epidemiology of Acinetobacter on a global level, as determined by pulsed-field gel electrophoresis (PFGE) and other techniques, and to assess whether patient outcomes are clonally related and to characterize the mechanisms of resistance in Acinetobacter on a global scale.
Study Overview
Status
Completed
Conditions
Detailed Description
Medical records will be reviewed and information collected from charts to assess for independent predictors of in-hospital mortality (up to 28 days) in patients with Acinetobacter bloodstream infection.
24 sites will participate and all information will be loaded into a password protected database.
Study Type
Observational
Enrollment (Actual)
400
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
acinetobacter infection
Description
Inclusion Criteria:
- Acinetobacter bloodstream infection
Exclusion Criteria:
- Does not meet entry criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2007
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
August 31, 2007
First Submitted That Met QC Criteria
August 31, 2007
First Posted (Estimate)
September 3, 2007
Study Record Updates
Last Update Posted (Actual)
June 12, 2018
Last Update Submitted That Met QC Criteria
June 11, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO07080042
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acinetobacter Infections
-
Entasis TherapeuticsCompletedAcinetobacter Baumannii-calcoaceticus Complex InfectionsUnited States
-
Entasis TherapeuticsCompletedAcinetobacter Baumannii-calcoaceticus Complex InfectionsUnited States
-
Entasis TherapeuticsCompletedAcinetobacter Baumannii InfectionAustralia
-
University Hospital, Strasbourg, FranceRecruitingAcinetobacter BaumanniiFrance
-
Gangnam Severance HospitalCompletedAcinetobacter Infections | Colistin | Rifampin
-
Entasis TherapeuticsCompletedBacteremia | Ventilator-associated Bacterial Pneumonia | Acinetobacter Baumannii-calcoaceticus Complex | Hospital-acquired Bacterial Pneumonia | Colistin Resistant ABCUnited States, Belarus, Brazil, China, Greece, Hungary, India, Israel, Korea, Republic of, Lithuania, Mexico, Peru, Puerto Rico, Russian Federation, Taiwan, Thailand, Turkey
-
University of PittsburghCompletedAcinetobacter InfectionsUnited States
-
Rambam Health Care CampusAssaf-Harofeh Medical Center; Sheba Medical Center; Monaldi Hospital; Rutgers Robert... and other collaboratorsNot yet recruitingCarbapenem Resistant Bacterial Infection | Acinetobacter Bacteremia | Acinetobacter Pneumonia
-
National Taiwan University HospitalFar Eastern Memorial HospitalUnknownAcinetobacter BacteraemiaTaiwan
-
Sutep JaruratanasirikulPrince of Songkla UniversityCompletedAcinetobacter InfectionsThailand